The consideration per share consisted of $21.00 in cash and one non-transferable contingent value right.

The parties entered into a definitive agreement on 22 October 2025 (as amended on 18 November 2025) which provided for the acquisition to occur by way of scheme of arrangement through the High Court of Ireland. Avadel Pharmaceuticals plc and Alkermes plc are each biopharmaceutical companies headquartered in Ireland. The transaction completed on 12 February 2026. We were pleased to work with Goodwin Procter LLP on this transaction.

Our team was led by Christopher McLaughlin and David Vos (Corporate and M&A) and included Tim Gleeson, Conor White and Iléna Germain (Corporate and M&A), Conall O’Shaughnessy, Niamh Egleston and Clodagh Prior (Litigation, Dispute Resolutions and Investigations), Fintan Clancy, Lebo Motsumi Nkoloti and Isobel D’Arcy (Tax), Simon Breen (Competition and Regulated Markets) and Ciara Buckley and Ross Mullen (Debt Finance).

For more information, please see: Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market | Alkermes plc